StreetAlpha.app
Home › Stocks › VERA

Vera Therapeutics, Inc. (VERA)

Healthcare
$25.45
▼ −4.86%
LAST CLOSE · NOV 20

Vera Therapeutics develops drug candidates for serious immune system diseases, led by atacicept for IgA nephropathy, a kidney disease. It last closed at $25.45 on Nov 20, down 4.86% on the day. The next earnings report for VERA is expected around Thu, Feb 25, 2027. For the quarter ended Sep 2026, VERA reported EPS of -$1.30 on revenue of $10.3M. Over its last 8 reports the stock moved an average of 3.4% the session after earnings. Over the last 12 months VERA insiders bought $250K of stock on the open market and sold $8.6M, according to SEC Form 4 filings.

AI Auto Pilots
Is VERA in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold VERA.

Key Stats

Last 12 months
Results
Net income
−$415.3M
EPS (diluted)
−$5.90
Free cash flow
−$376.0M
Valuation
Market cap
$1.8B
72.3M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$55.3M
At Sep 30
Debt
$75.4M
At Sep 30
Shareholder equity
$333.2M
Shares outstanding
72.3M
At Oct 29
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2021: −$32.6M−$32.6MFY2021FY2022: −$89.1M−$89.1MFY2022FY2023: −$96.0M−$96.0MFY2023FY2024: −$152.1M−$152.1MFY2024FY2025: −$299.6M−$299.6MFY2025

From VERA's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 5). Last 12 months adds up the four latest quarters.

Next report
Feb 25
Estimated date · Time not announced
Reported EPS
-$1.30
Quarter ended Sep 2026
Year ago EPS
-$1.26
Same quarter last year
Revenue
$10.3M
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.72Dec '24Mar 2025: -$0.81Mar '25Jun 2025: -$1.20Jun '25Sep 2025: -$1.26Sep '25Dec 2025: -$1.39Dec '25Mar 2026: -$1.69Mar '26Jun 2026: -$1.52Jun '26Sep 2026: -$1.30Sep '26Latest -$1.30
Revenue by quarter
Sep 2025: $0Sep '25Sep 2026: $10.3MSep '26Latest $10.3M
How VERA moved after its last 8 reports
Average move the session after a report ±3.4%
Nov 5, 2026After the close−1.2%
Aug 10, 2026After the close−4.1%
May 7, 2026Time not announced−1.9%
Feb 26, 2026Time not announced+1.6%
Nov 5, 2025Time not announced−1.0%
Aug 5, 2025Time not announced+0.9%
May 6, 2025Time not announced−13.8%
Feb 26, 2025Time not announced+2.5%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on VERAStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on VERA
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on VERA

Technical Analysis

VERA · as of the Nov 20 close · updated each morning
Downtrend, nearing oversold

The stock is 14% below its 20 day and 19% below its 50 day average. It is 40% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 36), near oversold. The nearest support is the 52 week low at $25.08, and the nearest resistance the Pivot at $25.92.

Short trendBearish
Long trendBearish
MomentumWeak
StretchNear oversold
VolatilityNormal, 6.5%/day
Key levels
$56.0552 week high+120.2%
$35.71200 day average+40.3%
$32.73100 day average+28.6%
$31.84Swing high (Oct 22)+25.1%
$30.2550 day average+18.9%
$29.1420 day average+14.5%
$26.68Pivot R1+4.8%
$25.92Pivot+1.8%
$25.45Last close
$25.0852 week low−1.5%
$24.69Pivot S1−3.0%
Indicators
RSI (14)35.94Weak, oversold below 30Neutral
MACD-1.13Below its signal lineBearish
Stochastic10.0Near the bottom of its rangeOversold
ADX (14)16.7No clear trend
Williams %R-94.8Oversold below −80, overbought above −20Oversold
CCI (20)-134.8Oversold below −100, overbought above 100Oversold
Rate of change−14.6%Change over 10 sessionsBearish
ATR (14)$1.65Typical daily range, 6.5% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for VERA

What happened before

See how VERA did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow VERA usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How VERA has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2021.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for VERAHow many large options trades hit VERA, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

VERA Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Bullish
Strongly bearishNeutralStrongly bullish
  • ▲129 buying vs 95 selling
  • ▲Held by funds +10.9 pts
  • ▲Funds holding +3
  • ▼Superinvestors: 1 added, 2 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding224221+1.4%
In funds' top 10137+85.7%
Held by funds118.7%107.8%+10.9 pts
New / increased39 / 9028 / 98+2.4%
Reduced / sold out58 / 3766 / 37−7.8%
Put/call ratio3.380.55+517.8%
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See VERA institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

VERA Insider Trading

All filings →
Insider trading · 12 months
Insiders are net sellers
Bought$250K1 buy · 1 insider
Sold$8.6M17 sales · 8 insiders
82% of the selling was under pre-arranged trading plans.
2025-12 bought $250K2025-12 sold $1.4M2026-02 sold $1.4M2026-04 sold $1.0M2026-05 sold $680K2026-06 sold $702K2026-07 sold $2.0M2026-09 sold $1.3MDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Sep 15Marshall FordycePresident And CEOSale plan18,500$37.00$685K
Sep 2Marshall FordycePresident And CEOSale plan18,500$35.12$650K
Jul 7Marshall FordycePresident And CEOSale plan46,250$42.30$2.0M
Jun 23Marshall FordycePresident And CEOSale plan18,500$37.93$702K
May 12Marshall FordycePresident And CEOSale plan18,500$36.74$680K
Apr 14Marshall FordycePresident And CEOSale plan22,951$44.05$1.0M
Every insider buy and sale for VERA over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See VERA insider trades →

From SEC Form 4 filings by VERA's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether VERA is in one of them and how their past VERA trades turned out.

VERA in the AI portfolios
Loading…

VERA News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered VERA in an article yet. Here's the latest on the wider market.

VERA in the news

About Vera Therapeutics

Vera Therapeutics is a biotechnology company based in Brisbane, California, that develops treatments for serious immune system diseases, with a focus on kidney conditions. Its lead candidate, atacicept, is being studied for IgA nephropathy, a kidney disease, and other autoimmune kidney disorders, and is designed to be given at home by autoinjector. The company also holds rights to MAU868, which is being studied for BK viremia in kidney transplant patients, and to VT109, a preclinical candidate. Its target customers are patients with these conditions and the doctors who treat them.

Headquarters
Brisbane, CA